Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma
, , et | 12 mai 2016
À propos de cet article
Article Category: Research Article
Publié en ligne: 12 mai 2016
Pages: 402 - 408
Reçu: 19 oct. 2015
Accepté: 31 janv. 2016
DOI: https://doi.org/10.1515/raon-2016-0028
Mots clés
© 2016 Radiol Oncol
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mean lymphocyte (Lym), natural killer (NK) and T regulatory (Treg) cell counts with 95 % confidence interval (CI) before mobilization, on collection day, in the leukapheresis product and on day 15 after autologous hematopoietic stem cell transplantation (D+15) for mobilization regimens using cyclophophamide, filgrastim (G-CSF) and pegfilgrastim
| Time point | Collection regimen | Cyclophosphamide | Pegfilgrastim | G-CSF | ||||
|---|---|---|---|---|---|---|---|---|
| Mean value | 95% CI | Mean value | 95% CI | Mean value | 95% CI | Sig | ||
| Before mobilization | Lym (× 109/L) | 1.81 | 1.27–2.34 | 1.48 | 1.17–1.80 | 1.43 | 1.20–1.66 | |
| NK (× 109/L) | 0.20 | 0.15–0.26 | 0.18 | 0.12–0.23 | 0.22 | 0.15–0.28 | ||
| Treg (× 106/L) | 8.53 | 4.1–12.9 | 10 | 5.28–14.6 | 6.86 | 4.24–9.48 | ||
| Collection day | Lym (× 109/L) | 1.08 | 0.52–1.64 | 3 | 2.46–3.54 | 3.08 | 2.65–3.51 | |
| NK (× 109/L) | 0.07 | 0.01–0.13 | 0.42 | 0.3–0.54 | 0.52 | 0.43–0.62 | ||
| Treg (× 106/L) | 14.4 | 3.73–25.1 | 20.4 | 12.4–28.5 | 18.5 | 10.6–26.4 | .646 | |
| Leukapheresis product | Lym(× 109/L) | 50.1 | 36–64.2 | 112 | 96.6–129 | 112 | 94.7–130 | |
| NK (× 109/L) | 4.18 | 0.72–7.64 | 14.3 | 11.9–16.6 | 17.5 | 12.7–22.4 | ||
| Treg (× 106/L) | 1030 | 392–1670 | 1030 | 400–1650 | 714 | 430–997 | 0.531 | |
| D+15 | Lym (× 109/L) | 0.31 | 0.14–0.47 | 0.47 | 0.38–0.55 | 0.47 | 0.36–0.59 | 0.115 |
| NK (× 109/L) | 0.05 | 0–0.85 | 0.10 | 0.04–0.16 | 0.10 | 0–0.34 | 0.357 | |
| Treg (× 106/L) | 27.8 | 4.45–51.1 | 36.6 | 0–101 | 2 | 0–5.74 | 0.691 | |
Patient characteristics
| Characteristics | Total number of patients | G-CSF mobilization | Pegfilgrastim mobilization | Cyclophosphamide mobilization |
|---|---|---|---|---|
| Numbers | 48 | 20 | 19 | 9 |
| Sex, M/F | 25 / 23 | 11 / 9 | 9 / 10 | 5 / 4 |
| Median age (Range) years | 61 (35–71) | 60 (35–69) | 64 (51–71) | 59 (42–63) |
| ISS stage 1/2/3 | 13/17/18 | 3/8/9 | 7/7/5 | 3/2/4 |
| Median cycles of chemotherapy | 4 | 4 | 4 | 4 |
| Patients with prior radiotherapy | 11 | 3 | 8 | 0 |
| Response VGPR/PR/SD | 11/9/0 | 10/8/1 | 3/5/1 | |
| Poor mobilizers | 3 | 1 | 2 | 0 |